David Shapiro Sells 2,000 Shares of Intercept Pharmaceuticals Inc (ICPT) Stock

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) insider David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $96.32, for a total transaction of $192,640.00. Following the sale, the insider now directly owns 41,152 shares of the company’s stock, valued at approximately $3,963,760.64. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

David Shapiro also recently made the following trade(s):

  • On Monday, October 15th, David Shapiro sold 3,425 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $102.95, for a total transaction of $352,603.75.
  • On Friday, October 5th, David Shapiro sold 759 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $110.65, for a total transaction of $83,983.35.
  • On Wednesday, September 5th, David Shapiro sold 4,917 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $111.43, for a total transaction of $547,901.31.

Intercept Pharmaceuticals stock opened at $109.55 on Friday. The company has a debt-to-equity ratio of 2.48, a current ratio of 6.51 and a quick ratio of 6.51. Intercept Pharmaceuticals Inc has a 1-year low of $51.05 and a 1-year high of $133.74.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.65) by $0.47. The business had revenue of $47.00 million for the quarter, compared to the consensus estimate of $48.24 million. Intercept Pharmaceuticals had a negative net margin of 202.93% and a negative return on equity of 903.22%. Intercept Pharmaceuticals’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter last year, the firm earned ($2.89) EPS. As a group, research analysts forecast that Intercept Pharmaceuticals Inc will post -10.2 earnings per share for the current year.

A number of equities research analysts have issued reports on the stock. Oppenheimer set a $100.00 target price on shares of Intercept Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday. Needham & Company LLC reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday. BidaskClub lowered shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 19th. Royal Bank of Canada reissued a “buy” rating and set a $115.00 target price on shares of Intercept Pharmaceuticals in a research note on Friday, August 3rd. Finally, Zacks Investment Research lowered shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th. Nine investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $139.88.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of Intercept Pharmaceuticals by 17.5% during the 2nd quarter. FMR LLC now owns 4,437,332 shares of the biopharmaceutical company’s stock valued at $372,336,000 after purchasing an additional 661,542 shares in the last quarter. First Trust Advisors LP raised its holdings in shares of Intercept Pharmaceuticals by 29.9% during the 3rd quarter. First Trust Advisors LP now owns 1,092,319 shares of the biopharmaceutical company’s stock valued at $138,025,000 after purchasing an additional 251,735 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Intercept Pharmaceuticals by 190.3% during the 2nd quarter. Northern Trust Corp now owns 257,755 shares of the biopharmaceutical company’s stock valued at $21,629,000 after purchasing an additional 168,955 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Intercept Pharmaceuticals by 168.9% during the 1st quarter. Millennium Management LLC now owns 235,180 shares of the biopharmaceutical company’s stock valued at $14,468,000 after purchasing an additional 147,719 shares in the last quarter. Finally, Peregrine Capital Management LLC raised its holdings in shares of Intercept Pharmaceuticals by 31.4% during the 2nd quarter. Peregrine Capital Management LLC now owns 151,434 shares of the biopharmaceutical company’s stock valued at $12,707,000 after purchasing an additional 36,189 shares in the last quarter. Institutional investors and hedge funds own 69.27% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

See Also: Intrinsic Value and Stock Selection

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply